← Issue №19/ week of Nov 8, 2026/IBD

Performance of an infliximab precision-guided dosing tool from a capillary blood-based self-collection device in inflammatory bowel disease patients.

From GI Signals issue №19: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD prospective cohort · n=57 · Nov 5, 2026 · Inflamm Bowel Dis · IF 4.5

Performance of an infliximab precision-guided dosing tool from a capillary blood-based self-collection device in inflammatory bowel disease patients.

Basic sciencebiologicstherapeutic drug monitoringartificial intelligencebiomarker
Clinical takeawayCapillary self-collection devices for infliximab trough level monitoring show promise in IBD patients, but further validation and availability are needed before clinical implementation.
What it foundCapillary self-collection of infliximab trough levels correlated strongly with venous blood measurement (R2 = 0.987, Demings = 1.08).
ContextThis feasibility study in 57 IBD patients (median age 34 years) at a single center demonstrates that capillary self-collection yields results comparable to venous blood sampling.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Law CCY … Colombel JF · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
← Read the whole of issue №19 Every paper GI Signals surfaces gets a page like this one. All issues